SG10201706063UA - Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same - Google Patents

Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same

Info

Publication number: SG10201706063UA
Authority: SG; Singapore
Prior art keywords: neuroactive; prodrugs; alkoxy; treatment; methods
Prior art date: 2012-12-18

Application number

SG10201706063UA

Inventor

Douglas Covey

Albert Jean Robichaud

Original Assignee

Univ Washington

Sage Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-12-18

Filing date

2013-12-18

Publication date

2017-09-28

2013-12-18 Application filed by Univ Washington, Sage Therapeutics Inc filed Critical Univ Washington

2017-09-28 Publication of SG10201706063UA publication Critical patent/SG10201706063UA/en

Links

239000000651 prodrug Chemical class 0.000 title 1
229940002612 prodrug Drugs 0.000 title 1
150000003431 steroids Chemical class 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
- C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0029—Ethers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
- C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C07J21/006—Ketals at position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C07J21/008—Ketals at position 17
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0016—Oximes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

SG10201706063UA 2012-12-18 2013-12-18 Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same SG10201706063UA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201261738822P	2012-12-18	2012-12-18

Publications (1)

Publication Number	Publication Date
SG10201706063UA true SG10201706063UA (en)	2017-09-28

Family

ID=50979162

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SG11201504848QA SG11201504848QA (en)	2012-12-18	2013-12-18	Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
SG10201706063UA SG10201706063UA (en)	2012-12-18	2013-12-18	Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
SG10201809638YA SG10201809638YA (en)	2012-12-18	2013-12-18	Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SG11201504848QA SG11201504848QA (en)	2012-12-18	2013-12-18	Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG10201809638YA SG10201809638YA (en)	2012-12-18	2013-12-18	Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same

Country Status (27)

Country	Link
US (7)	US9630986B2 (en)
EP (3)	EP2935307B1 (en)
JP (4)	JP6542127B2 (en)
KR (3)	KR102400891B1 (en)
CN (3)	CN109970833B (en)
AU (4)	AU2013361485B2 (en)
BR (1)	BR112015014397B1 (en)
CA (1)	CA2895513C (en)
CY (1)	CY1121150T1 (en)
DK (1)	DK2935307T3 (en)
ES (2)	ES2933987T3 (en)
HK (1)	HK1216255A1 (en)
HR (1)	HRP20181048T1 (en)
HU (1)	HUE039057T2 (en)
IL (3)	IL278396B1 (en)
LT (1)	LT2935307T (en)
MX (2)	MX365644B (en)
NZ (2)	NZ709211A (en)
PH (2)	PH12018502141A1 (en)
PL (1)	PL2935307T3 (en)
PT (2)	PT2935307T (en)
RS (1)	RS57390B1 (en)
RU (1)	RU2663665C2 (en)
SG (3)	SG11201504848QA (en)
SI (2)	SI2935307T1 (en)
TR (1)	TR201808616T4 (en)
WO (1)	WO2014100228A1 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EA017290B1 (en)	2005-11-28	2012-11-30	Домейн Раша Инвестментс Лимитед	Ganaxolone-based formulations
LT2753632T (en)	2011-09-08	2023-07-10	Sage Therapeutics, Inc.	Neuroactive steroids, compositions, and uses thereof
ES2738526T3 (en)	2011-10-14	2020-01-23	Sage Therapeutics Inc	Compounds 19-norpregnano 3,3-disubstituted, compositions and uses thereof
IL298436B1 (en)	2012-01-23	2024-03-01	Sage Therapeutics Inc	Pharmaceutical compositions comprising allopregnanolone
BR112015014397B1 (en) *	2012-12-18	2021-02-02	Washington University	compound, pharmaceutical composition and use of a compound
ES2699445T3 (en)	2013-03-13	2019-02-11	Sage Therapeutics Inc	Neuroactive steroids and methods of using them
CA2909546C (en)	2013-04-17	2019-01-22	Sage Therapeutics, Inc.	19-nor neuroactive steroids and methods of use thereof
WO2014169836A1 (en)	2013-04-17	2014-10-23	Sage Therapeutics, Inc.	19-nor neuroactive steroids and methods of use thereof
US9725481B2 (en)	2013-04-17	2017-08-08	Sage Therapeutics, Inc.	19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
EP3498725B1 (en)	2013-04-17	2021-06-09	Sage Therapeutics, Inc.	19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for use in therapy
CN105555277B (en) *	2013-07-19	2022-01-11	萨奇治疗股份有限公司	Neuroactive steroid compounds, compositions and uses thereof
AU2014308621C1 (en)	2013-08-23	2022-01-06	Sage Therapeutics, Inc.	Neuroactive steroids, compositions, and uses thereof
US10246482B2 (en)	2014-06-18	2019-04-02	Sage Therapeutics, Inc.	Neuroactive steroids, compositions, and uses thereof
US10259840B2 (en)	2014-06-18	2019-04-16	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
JOP20200195A1 (en)	2014-09-08	2017-06-16	Sage Therapeutics Inc	Neuroactive steroids, compositions, and uses thereof
ES2808855T3 (en)	2014-10-16	2021-03-02	Sage Therapeutics Inc	Compositions and methods for treating CNS disorders
CN117024502A (en)	2014-10-16	2023-11-10	萨奇治疗股份有限公司	Compositions and methods for targeting CNS disorders
SI3224269T1 (en)	2014-11-27	2020-10-30	Sage Therapeutics, Inc.	Compositions and methods for treating cns disorders
PL3250210T3 (en)	2015-01-26	2021-07-26	Sage Therapeutics, Inc.	Compositions and methods for treating cns disorders
JP6875996B2 (en) *	2015-02-20	2021-05-26	セージセラピューティクス，インコーポレイテッド	Neurostimulatory steroids, compositions, and their use
MA45276A (en)	2015-06-18	2018-04-25	Sage Therapeutics Inc	NEUROACTIVE STEROID SOLUTIONS AND THEIR METHODS OF USE
MX2020010690A (en)	2015-07-06	2022-02-25	Sage Therapeutics Inc	Oxysterols and methods of use thereof.
CA2991311A1 (en)	2015-07-06	2017-01-12	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
IL256710B2 (en)	2015-07-06	2024-01-01	Sage Therapeutics Inc	Oxysterols and methods of use thereof
KR20180082457A (en)	2015-10-16	2018-07-18	마리누스 파마슈티컬스 인코포레이티드	Injectable neuro-steroid agents containing nanoparticles
WO2017087864A1 (en) *	2015-11-20	2017-05-26	Sage Therapeutics, Inc.	Compounds and methods of their use
MA43815A (en)	2016-03-08	2021-04-07	Sage Therapeutics Inc	NEUROACTIVE STEROIDS, COMPOSITIONS, AND THEIR USES
PL3436022T3 (en)	2016-04-01	2022-08-08	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
US10752653B2 (en)	2016-05-06	2020-08-25	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
SI3481846T1 (en)	2016-07-07	2021-11-30	Sage Therapeutics, Inc.	11-substituted 24-hydroxysterols for use in the treatment of nmda related conditions
JP7049313B2 (en)	2016-07-11	2022-04-06	セージセラピューティクス，インコーポレイテッド	C17, C20, and C21 substitution neurostimulatory steroids and how to use them
JP2019524816A (en)	2016-08-11	2019-09-05	オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	Methods and compositions for the treatment of epileptic disorders
WO2018039378A1 (en)	2016-08-23	2018-03-01	Sage Therapeutics, Inc.	A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
US10391105B2 (en)	2016-09-09	2019-08-27	Marinus Pharmaceuticals Inc.	Methods of treating certain depressive disorders and delirium tremens
ES2935057T3 (en)	2016-09-30	2023-03-01	Sage Therapeutics Inc	C7 substituted oxysterols and these compounds for use as NMDA modulators
CA3234484A1 (en)	2016-10-18	2018-04-26	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
RU2019115112A (en)	2016-10-18	2020-11-24	Сейдж Терапьютикс, Инк.	OXYSTEROLES AND METHODS OF THEIR APPLICATION
KR20200096596A (en)	2017-12-08	2020-08-12	세이지 테라퓨틱스, 인크.	Deuterated 21-[4-cyano-pyrazole-1-yl]-19-nor-pregan-3 for the treatment of CNS disorders. Alpha-ol-20-one derivative
CN109988210B (en) *	2017-12-30	2022-05-17	天津药业研究院股份有限公司	Preparation method of progesterone and progesterone intermediate
AU2019357040A1 (en)	2018-10-12	2021-05-20	Sage Therapeutics, Inc.	Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of CNS disorders
CN109289095B (en) *	2018-11-23	2021-03-26	淮海工学院	Enteroscope gel containing lidocaine hydrochloride and preparation method thereof
WO2020118142A1 (en)	2018-12-07	2020-06-11	Marinus Pharmaceuticals, Inc.	Ganaxolone for use in prophylaxis and treatment of pospartum depression
JOP20210293A1 (en)	2019-05-31	2023-01-30	Sage Therapeutics Inc	Neuroactive steroids and compositions thereof
WO2021026124A1 (en)	2019-08-05	2021-02-11	Marinus Pharmaceuticals, Inc.	Ganaxolone for use in treatment of status epilepticus
US10857163B1 (en)	2019-09-30	2020-12-08	Athenen Therapeutics, Inc.	Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
KR20220134529A (en)	2019-12-06	2022-10-05	마리누스 파마슈티컬스 인코포레이티드	Ganaxolone for use in the treatment of complex tuberous sclerosis
AU2021241622A1 (en)	2020-03-25	2022-10-20	Sage Therapeutics, Inc.	Use of agents for treatment of respiratory conditions

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB820779A (en) *	1954-12-08	1959-09-23	Syntex Sa	Cyclopentanophenanthrene derivatives
US2856415A (en) *	1957-11-13	1958-10-14	Searle & Co	3,19-dihydroxy-5-androstene derivatives
BE632431A (en) *	1962-05-16
US3206459A (en)	1962-10-19	1965-09-14	Syntex Corp	10alpha-pregnan-19-ol derivatives
US4239681A (en) *	1974-04-15	1980-12-16	Richardson-Merrell Inc.	Androst-4-en-19-ols
US4071625A (en)	1974-05-13	1978-01-31	Richardson-Merrell Inc.	19-Oxygenated-5α-androstanes for the enhancement of libido
US4022769A (en) *	1974-05-13	1977-05-10	Richardson-Merrell Inc.	Androst-4-en-19-ones
US4139617A (en) *	1974-05-13	1979-02-13	Richardson-Merrell Inc.	19-Oxygenated-androst-5-enes for the enhancement of libido
DE2632677A1 (en)	1976-07-16	1978-01-26	Schering Ag	PROCESS FOR THE MANUFACTURE OF ANDROSTANE-17-ONE DERIVATIVES AND THEIR USE
MA18433A1 (en) *	1978-05-26	1979-12-31	Ciba Geigy Ag	PROCESS FOR THE SYNTHESIS OF THE HYDROXYACETYL SIDE CHAIN OF PREGNAGNE-TYPE STEROIDS, NEW 21-HYDROXY-20-OXO-17 ALPHA-PREGNAGNES AND PHARMACEUTICAL PRODUCTS CONTAINING
US4389345A (en)	1981-10-09	1983-06-21	G.D. Searle & Co.	3-Oxoestra-17-acetonitrile and unsaturated analogs
US4495102A (en) *	1982-09-03	1985-01-22	G. D. Searle & Co.	Aminoalkyl steroids
US5232917A (en)	1987-08-25	1993-08-03	University Of Southern California	Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
EP0656365B1 (en)	1993-12-02	1997-04-09	Akzo Nobel N.V.	Substituted 2beta-morpholinoandrostane derivatives
US5661141A (en) *	1995-03-27	1997-08-26	Petrow; Vladimir	19-oxygenated steroids as therapeutic agents
ATE284895T1 (en) *	1995-06-06	2005-01-15	Euro Celtique Sa	NEUROACTIVE STEROIDS OF THE ANDROSTANE AND PREGNAN SERIES
US6855836B2 (en)	2000-10-26	2005-02-15	Jenapharm Gmbh & Co. Kg	17-Methylene steroids, process for their production and pharmaceutical compositions that contain these compounds
AU2002232509A1 (en)	2000-11-03	2002-05-15	Washington University	Estrone-derivatives having cytoprotective activity
GR1003861B (en) *	2000-12-29	2002-04-11		Novel gabaa modulating neurosteroids
BRPI0408703A (en)	2003-03-24	2006-03-07	Sterix Ltd	estrogen derivatives as steroid sulfatase inhibitors
CN1281561C (en) *	2003-04-23	2006-10-25	中国科学院上海有机化学研究所	Compound with base skeleton of 1,6-methylene-[10]-annulene and use thereof
CA2527019A1 (en)	2003-05-29	2005-01-06	Washington University	Neuroactive 13,24-cyclo-18,21-dinorcholanes and structurally-related pentacyclic steroids
AU2004292555A1 (en) *	2003-11-24	2005-06-09	Merck & Co., Inc.	Estrogen receptor modulators
DE102007027636A1 (en)	2007-06-12	2008-12-18	Bayer Schering Pharma Aktiengesellschaft	17β-Cyano-18α-homo-19-nor-androst-4-ene derivative, its use and the derivative-containing drug
WO2008157460A1 (en)	2007-06-15	2008-12-24	Cook, Kevin, M.	Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties
GB0711948D0 (en)	2007-06-20	2007-08-01	Bionature E A Ltd	Neurosteriod compounds
AU2011284606A1 (en) *	2010-07-30	2013-03-14	Pharmacellion Ltd	Compounds and methods for treating neoplasia
AU2011343615A1 (en)	2010-12-15	2013-05-09	Harbor Biosciences, Inc.	Methods and compounds for preparing 3alpha-oxygen substituted steroids
WO2012116290A2 (en)	2011-02-25	2012-08-30	Washington University	Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
ES2762098T3 (en)	2011-03-23	2020-05-22	Etsuro Ito	Method and kit for measuring super high sensitivity of protein and nucleic acid, and a new enzyme substrate
WO2013188792A2 (en) *	2012-06-15	2013-12-19	Sage Therapeutics, Inc.	Neuroactive steroids, compositions, and uses thereof
WO2014058736A1 (en) *	2012-10-08	2014-04-17	Washington University	Neuroactive 19-alkoxy-17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
BR112015014397B1 (en)	2012-12-18	2021-02-02	Washington University	compound, pharmaceutical composition and use of a compound
US9562026B2 (en) *	2013-03-14	2017-02-07	Washington University	Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors
AU2014308621C1 (en) *	2013-08-23	2022-01-06	Sage Therapeutics, Inc.	Neuroactive steroids, compositions, and uses thereof

2013
- 2013-12-18 BR BR112015014397-0A patent/BR112015014397B1/en active IP Right Grant
- 2013-12-18 RS RS20180807A patent/RS57390B1/en unknown
- 2013-12-18 KR KR1020217017732A patent/KR102400891B1/en active IP Right Grant
- 2013-12-18 AU AU2013361485A patent/AU2013361485B2/en active Active
- 2013-12-18 US US14/132,386 patent/US9630986B2/en active Active
- 2013-12-18 ES ES18162373T patent/ES2933987T3/en active Active
- 2013-12-18 PT PT138654116T patent/PT2935307T/en unknown
- 2013-12-18 SG SG11201504848QA patent/SG11201504848QA/en unknown
- 2013-12-18 MX MX2015007900A patent/MX365644B/en active IP Right Grant
- 2013-12-18 EP EP13865411.6A patent/EP2935307B1/en active Active
- 2013-12-18 PT PT181623737T patent/PT3392260T/en unknown
- 2013-12-18 CN CN201811630997.3A patent/CN109970833B/en active Active
- 2013-12-18 TR TR2018/08616T patent/TR201808616T4/en unknown
- 2013-12-18 NZ NZ709211A patent/NZ709211A/en unknown
- 2013-12-18 DK DK13865411.6T patent/DK2935307T3/en active
- 2013-12-18 US US14/652,717 patent/US9676812B2/en active Active
- 2013-12-18 HU HUE13865411A patent/HUE039057T2/en unknown
- 2013-12-18 IL IL278396A patent/IL278396B1/en unknown
- 2013-12-18 SG SG10201706063UA patent/SG10201706063UA/en unknown
- 2013-12-18 CN CN202210026684.7A patent/CN114605486A/en active Pending
- 2013-12-18 KR KR1020157019442A patent/KR101993899B1/en active IP Right Grant
- 2013-12-18 WO PCT/US2013/076214 patent/WO2014100228A1/en active Application Filing
- 2013-12-18 NZ NZ739760A patent/NZ739760A/en unknown
- 2013-12-18 KR KR1020197018089A patent/KR102265408B1/en active IP Right Grant
- 2013-12-18 SG SG10201809638YA patent/SG10201809638YA/en unknown
- 2013-12-18 PL PL13865411T patent/PL2935307T3/en unknown
- 2013-12-18 SI SI201331092T patent/SI2935307T1/en unknown
- 2013-12-18 CA CA2895513A patent/CA2895513C/en active Active
- 2013-12-18 LT LTEP13865411.6T patent/LT2935307T/en unknown
- 2013-12-18 CN CN201380072706.2A patent/CN105026415B/en active Active
- 2013-12-18 ES ES13865411.6T patent/ES2680582T3/en active Active
- 2013-12-18 SI SI201332021T patent/SI3392260T1/en unknown
- 2013-12-18 RU RU2015129546A patent/RU2663665C2/en active
- 2013-12-18 EP EP22166199.4A patent/EP4086270A1/en active Pending
- 2013-12-18 EP EP18162373.7A patent/EP3392260B1/en active Active
- 2013-12-18 IL IL310501A patent/IL310501A/en unknown
- 2013-12-18 PH PH12018502141A patent/PH12018502141A1/en unknown
- 2013-12-18 JP JP2015549643A patent/JP6542127B2/en active Active
2015
- 2015-06-18 PH PH12015501404A patent/PH12015501404B1/en unknown
- 2015-06-18 MX MX2019006739A patent/MX2019006739A/en unknown
- 2015-06-18 IL IL239501A patent/IL239501B/en active IP Right Grant
2016
- 2016-04-14 HK HK16104261.6A patent/HK1216255A1/en unknown
2017
- 2017-03-15 US US15/459,492 patent/US10342809B2/en active Active
- 2017-05-04 US US15/586,853 patent/US20170232006A1/en not_active Abandoned
2018
- 2018-07-03 CY CY20181100686T patent/CY1121150T1/en unknown
- 2018-07-05 HR HRP20181048TT patent/HRP20181048T1/en unknown
- 2018-08-14 AU AU2018217213A patent/AU2018217213B2/en active Active
2019
- 2019-05-22 US US16/419,255 patent/US20200113916A1/en not_active Abandoned
- 2019-06-12 JP JP2019109822A patent/JP6852118B2/en active Active
2020
- 2020-03-20 AU AU2020202016A patent/AU2020202016C1/en active Active
2021
- 2021-03-10 JP JP2021038515A patent/JP7241792B2/en active Active
- 2021-06-21 US US17/304,433 patent/US20210308149A1/en active Pending
- 2021-12-20 AU AU2021290223A patent/AU2021290223B2/en active Active
2023
- 2023-02-09 US US18/107,965 patent/US20230190770A1/en not_active Abandoned
- 2023-03-07 JP JP2023034402A patent/JP2023071910A/en active Pending

Also Published As

Publication number	Publication date
EP2935307A1 (en)	2015-10-28
HUE039057T2 (en)	2018-12-28
US9630986B2 (en)	2017-04-25
KR101993899B1 (en)	2019-09-24
JP2023071910A (en)	2023-05-23
NZ709211A (en)	2018-02-23
WO2014100228A1 (en)	2014-06-26
EP4086270A1 (en)	2022-11-09
AU2018217213B2 (en)	2020-03-12
JP7241792B2 (en)	2023-03-17
AU2021290223B2 (en)	2024-01-18
PT2935307T (en)	2018-07-31
RU2663665C2 (en)	2018-08-08
JP2021098739A (en)	2021-07-01
AU2018217213A1 (en)	2018-08-30
HK1216255A1 (en)	2016-10-28
EP3392260B1 (en)	2022-09-21
CY1121150T1 (en)	2020-05-29
SI3392260T1 (en)	2023-01-31
US20170152282A9 (en)	2017-06-01
BR112015014397B1 (en)	2021-02-02
US20170232006A1 (en)	2017-08-17
US20140235600A1 (en)	2014-08-21
NZ739760A (en)	2020-05-29
CN109970833A (en)	2019-07-05
AU2013361485B2 (en)	2018-05-17
TR201808616T4 (en)	2018-07-23
MX365644B (en)	2019-06-10
US20210308149A1 (en)	2021-10-07
JP6852118B2 (en)	2021-03-31
CN114605486A (en)	2022-06-10
CA2895513C (en)	2021-04-27
LT2935307T (en)	2018-07-25
EP2935307A4 (en)	2016-08-03
EP2935307B1 (en)	2018-04-25
AU2020202016A1 (en)	2020-04-09
US10342809B2 (en)	2019-07-09
AU2020202016B2 (en)	2021-09-23
CN109970833B (en)	2022-05-27
PH12015501404A1 (en)	2015-09-07
MX2019006739A (en)	2019-08-22
PH12018502141A1 (en)	2019-04-15
SG10201809638YA (en)	2018-11-29
SG11201504848QA (en)	2015-07-30
IL239501B (en)	2020-11-30
JP6542127B2 (en)	2019-07-10
ES2933987T3 (en)	2023-02-15
KR20190076072A (en)	2019-07-01
RS57390B1 (en)	2018-09-28
US20230190770A1 (en)	2023-06-22
AU2020202016C1 (en)	2022-03-24
SI2935307T1 (en)	2018-08-31
JP2019182870A (en)	2019-10-24
EP3392260A1 (en)	2018-10-24
PT3392260T (en)	2022-12-27
US20200113916A1 (en)	2020-04-16
KR102400891B1 (en)	2022-05-20
US20150315230A1 (en)	2015-11-05
PL2935307T3 (en)	2018-09-28
US9676812B2 (en)	2017-06-13
IL239501A0 (en)	2015-08-31
IL310501A (en)	2024-03-01
JP2016503793A (en)	2016-02-08
US20170190732A1 (en)	2017-07-06
KR20150100771A (en)	2015-09-02
ES2680582T3 (en)	2018-09-10
CN105026415B (en)	2019-02-01
CA2895513A1 (en)	2014-06-26
PH12015501404B1 (en)	2015-09-07
KR102265408B1 (en)	2021-06-16
MX2015007900A (en)	2016-02-05
HRP20181048T1 (en)	2018-08-24
KR20210072151A (en)	2021-06-16
DK2935307T3 (en)	2018-07-30
AU2021290223A1 (en)	2022-01-20
CN105026415A (en)	2015-11-04
AU2013361485A1 (en)	2015-07-09
IL278396B1 (en)	2024-03-01
IL278396A (en)	2020-12-31
RU2015129546A (en)	2017-01-24

Publication	Publication Date	Title
IL278396A (en)	2020-12-31	Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
IL286970A (en)	2021-12-01	Neuroactive steroids and methods of use thereof
HRP20181994T1 (en)	2019-03-08	Neuroactive steroids and methods of use thereof
LT2986624T (en)	2020-07-10	19-nor neuroactive steroids for methods of treatment
HK1204281A1 (en)	2015-11-13	Neuroactive steroid formulations and methods of treating cns disorders (cns)
EP2744852A4 (en)	2015-04-15	Plasma modified medical devices and methods
EP2861538A4 (en)	2015-12-30	Bioconversion processes and apparatus
ZA201501601B (en)	2016-01-27	Virus purification and formulation process
HK1216727A1 (en)	2016-12-02	Syringe devices, components of syringe devices, and methods of forming components and syringe devices
GB201221118D0 (en)	2013-01-09	Methods of treatment
GB201216740D0 (en)	2012-10-31	Methods of treatment
GB201216748D0 (en)	2012-10-31	Methods of treatment
GB201206325D0 (en)	2012-05-23	Methods of treatment
GB201206326D0 (en)	2012-05-23	Methods of treatment
GB201206324D0 (en)	2012-05-23	Methods of treatment
GB201206330D0 (en)	2012-05-23	Methods of treatment